In the SLE group, median SLEDAI
score was 10 (0-30); median levels of [C.
The majority of the SLE patients had maPRL, but no differences were seen regarding the mean age, SLEDAI
scores, autoantibodies, or C3 levels in either these SLE patients or those without this characteristic (Table 3).
There were no significant changes in anti-dsDNA titers, C3 or C4 levels, or SLEDAI
and PGA scores at any of the time points, Dr.
The primary efficacy endpoint of BLISS-52 and BLISS-76 is the patient response rate at Week 52, as defined by: (1) a reduction from baseline of at least 4 points on the SELENA SLEDAI
disease activity scale (which indicates a clinically important reduction in SLE disease activity); (2) no worsening of disease as measured by the Physician's Global Assessment (worsening defined as an increase of 0.
Post hoc exploratory analyses of BLISS-76 data at Weeks 52 and 76 evaluated SRI response using greater SELENA SLEDAI
reductions (-5, -6, -7, -8, -9 and -10 points) than the 4-point reduction used for the primary endpoint.
Furthermore, the Mann-Whitney U test analysis for nonparametric data was used to compare the clinical data between the two groups, and Pearson's correlation coefficient was used to analyze any correlations between the SLEDAI
Lower levels correlated with higher SLEDAI
(Systemic Lupus Erythematosus Disease Activity Index) scores and higher anti-dsDNA antibody levels, Dr.
The second group had active stable disease with a SLEDAI
between 5 and 12.
Post hoc exploratory analyses to be presented at EULAR evaluated SRI response in BLISS-52 using greater SELENA SLEDAI
reductions (-5, -6, or -7 or more points) than the 4-point reduction used for the primary endpoint.
They also compared the SLEDAI
scores of the both the patients with and without DV and found that those with DV had milder systemic involvement compared with the other patients.
3] levels correlated with disease activity, with levels being significantly lower among patients whose SLEDAI
scores were greater than 4 (mean 12.
The primary efficacy endpoint of BLISS-76 was the patient response rate at Week 52 as measured by the SLE Responder Index (SRI), which defines patient response by an improvement in SELENA SLEDAI
score of 4 points or greater, with no clinically significant BILAG worsening, and no clinically significant worsening in Physician's Global Assessment.